Login / Signup
Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.
Krystal L Edwards
Molly G Minze
Published in:
Core evidence (2015)
Dulaglutide is a once-weekly GLP-1 RA approved for the treatment of T2DM that has shown similar efficacy to other agents in this class.
Keyphrases
</>
systemic lupus erythematosus
metabolic syndrome
adipose tissue
glycemic control
smoking cessation
interstitial lung disease